Clinical Trial Evidence for HER2-Targeted Therapies in Early Breast Cancer

Panelists discuss how recent data from pivotal studies are reshaping the early-stage HER2-positive breast cancer treatment paradigm. The conversation covers key trials evaluating antibody-–drug conjugates (ADCs) and novel combinations that improve disease-free and overall survival while minimizing toxicity.

They explore how the latest findings influence neoadjuvant and adjuvant strategies, with a focus on balancing efficacy and quality of life. Evidence is assessed for its practical impact on community practice, highlighting which regimens may soon become the standard of care.

The group reflects on the differences between trial results and real-world implementation challenges, emphasizing multidisciplinary coordination and patient-centered decision-making.